Aktuelle Masterarbeitsthemen der Forschungsgruppe Molekulare Pharmazie
Current Master's Theses-Projects of the Research Group in Molecular Pharmacy


Research Field
Kontakt Betreuer/in
Contact Supervisor
MSc PharmazieMSc Drug SciencesBemerkungen
Point-of-Care-Diagnostics for Preeclampsia (Development of sensitive, antibody-based in-vitro diagnostic rapid tests)
Project description English
Project description German
Prof. Dr. Daniel RicklinneinjaExternal master’s thesis with MOMM Diagnostics GmbH and FHNW. Preferred project start in August 2021 or earlier;
first contact Prof. Dr. Daniel Ricklin
Development of peptide-based strategies for host cell/biomaterial protection and targeting.Clément Bechtlerjaja
Development of Carbohydrate-based Mimics as Ligands for Siglec-8PD Dr. Oliver SchwardtjaneinProject description
Evaluation of physiological or therapeutic immune modulators of the complement/coagulation system.Dr. Richard Pouwjaja

Synthesis and development of carbohydrate-based molecules to reduce pathogen virulence

Dr. Rachel Heveyjaja

Design, synthesis, and evaluation of carbohydrate-based modulators of host defense

Dr. Rachel Heveyjaja
Synthesis and development of glycopolymers for treating blood group-incompatible transplantationsDr. Rachel HeveyjajaCollaboration with University Start-up Polyneuron Pharmaceuticals AG
In vitro assessment of glycopolymers for enabling blood group-incompatible transplantationsDr. Rachel HeveyjajaCollaboration with University Start-up Polyneuron Pharmaceuticals AG
Cloning, expression, purification and evaluation of therapeutically relevant proteins involved in the modulation of immune and inflammatory responses.Dr. Said RabbanijajaProject description
Discovery and evaluation of novel complement inhibitors using phage-display library screening and peptide synthesis.Dr. Christina Lamersjaja
Development of a human stem cell-derived in vitro assay to assess the DMPK properties of new drug candidatesDr. Pascal HänggijajaCollaboration with University Start-up Polyneuron Pharmaceuticals AG; first contact Prof. Dr. Daniel Ricklin and Dr. Pascal Hänggi
no longer available
Preparation of protein-based targets and modulators of the innate immune system and their evaluation in bioassays.
Dr. Said Rabbanijaja
no longer available
Design and synthesis of glycomimetic ligands for Siglec-8, a new target for eosinophil and mast-cell related disorders.
Benedetta Girardijaja
no longer available
Removal of autoantibodies against glycans - Biological and biophysical characterization of autoantibody-glycopolymer complexes
Butrint AliujajaCollaboration with University Start-up Polyneuron Pharmaceuticals AG; 
no longer available
Beyond anti-glycan autoantibody removal - In vivo and in vitro assessment of the immune modulatory potential of glycopolymers for the treatment of autoimmune diseases
Dr. Emilie SeydouxjajaCollaboration with University Start-up Polyneuron Pharmaceuticals AG; 
no longer available
Novel Anti-Inflammatories: Identification of Selectin Antagonists by a Dynamic Combinatorial Chemistry Approach
Prof. em. Dr. Beat Ernstjajapreferred MSc Drug Sciences
no longer available
Evaluation and Summarization Praktikum
PD Dr. Oliver Schwardtjaja

no longer available
Development of a new class of radiopharmaceuticals for diagnosis and therapy of CXCR4-expressing malignancies

Prof. Dr. Daniel RicklinjajaCollaboration with Universitätsspital Basel
Project description
no longer available
Establishment and validation of a Mannan-induced psoriasis arthritis-like disease model in mice
Prof. Dr. Daniel RicklinneinjaMasterthesis with Idorsia; first contact Prof. Dr. Daniel Ricklin

no longer available
Integrin Receptor-Targeted Immune Modulation: Target Production, Bioassay Development and Evaluation of Inhibitors

Carla Plüssjaja
no longer available
Protein engineering for the development of inhibitors of host defense pathway initiation.
Kevin Widmerjaja
no longer available
Discovery and synthesis of CD59 inhibitors to potentiate antibody-based leukemia treatment
Dr. Christina Lamersjaja
no longer available
DC-SIGN Antagonists to Block the Viral Entry to Dendritic Cells
Dr. Jonathan Cramerjajapreferred MSc Drug Sciences